TCGA-D8-A1XS-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.430
- E2F_TARGETS+0.390
- G2M_CHECKPOINT+0.360
- ANDROGEN_RESPONSE+0.340
- MYC_TARGETS_V1+0.320
- MITOTIC_SPINDLE+0.270
- PI3K_AKT_MTOR_SIGNALING+0.270
- UV_RESPONSE_DN+0.260
- MTORC1_SIGNALING+0.230
- ESTROGEN_RESPONSE_EARLY+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- PANCREAS_BETA_CELLS-0.340
- INTERFERON_GAMMA_RESPONSE-0.300
- MYOGENESIS-0.290
- COAGULATION-0.250
- KRAS_SIGNALING_DN-0.250
- ALLOGRAFT_REJECTION-0.210
- HEDGEHOG_SIGNALING-0.210
- TNFA_SIGNALING_VIA_NFKB-0.200
- UV_RESPONSE_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A2LK-01A-11R-A180-07 | — | B | 0.811 |
| 2 | MNG1168 | — | — | 0.804 |
| 3 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.796 |
| 4 | MBCProject_5953_T1_RNA | — | B | 0.786 |
| 5 | TCGA-A8-A07B-01A-11R-A00Z-07 | — | C | 0.786 |
| 6 | MDT-AP-0138 | Med | Medulloblastoma | 0.774 |
| 7 | MDT-AP-3334 | Med | Medulloblastoma | 0.774 |
| 8 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.769 |
| 9 | MDT-AP-3297 | Med | Medulloblastoma | 0.766 |
| 10 | R318 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |